Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03727646
Other study ID # STUDY00005431
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date September 26, 2018
Est. completion date November 26, 2018

Study information

Verified date August 2020
Source University of Washington
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

While preliminary data show that oral nicotinamide riboside (NR) supplementation increases myocardial levels of oxidized nicotine-adenine dinucleotide (NAD+) levels in mice, there has been no direct evidence that suggests oral NR increases NAD+ levels or improves mitochondrial function in human hearts. This Pilot Study is designed to obtain feasibility data for a planned, larger study testing the hypothesis that oral NR supplementation will increase myocardial NAD+ levels and improve cardiomyocyte mitochondrial function in participants with advanced heart failure planned for elective left ventricular assist device (LVAD) implantation. To demonstrate safety and feasibility of NR in this patient population, the investigators propose to enroll 5 participants planned for LVAD implantation in a Pilot Study of NR in which participants will receive NR, up-titrated over 3 days to a final NR dose of 1000mg twice daily. Blood and myocardial tissue analyses collected previously from age- and gender-matched LVAD recipients will serve as controls.


Description:

This Pilot Study will examine the following Aims:

Aim 1: Enroll 5 participants scheduled for elective left ventricular assist device (LVAD) placement into an open-label study of nicotinamide riboside (NR).

a. Participants will have labs (including safety panels) drawn at baseline (Day 1), then receive escalating doses of NR to a maximum dose of 1000mg twice daily by Day 3. Participants will be continued on NR at 1000mg twice daily until LVAD implantation surgery.

On the morning of LVAD implantation Surgery (Day 5 or later), participants will have final labs drawn. Samples of fresh cardiac tissue removed from the left ventricular apex during LVAD implantation surgery will be collected in the operating room. The primary analyses will be performed on NR-treated participants who were on the maximum NR dose of 1000mg twice daily for at least 2 days prior to LVAD implantation surgery. The maximum duration of NR administration will be capped at 14 days. If the surgery doesn't happen by then, the participant will be withdrawn from the study.

Aim 2: Determine the effect of NR (as compared to historical controls) on levels of the oxidized and reduced forms of nicotine-adenine dinucleotide (NAD+ and NADH, respectively), mitochondrial function and its regulation through modifications of the epigenome in the failing myocardium.

1. Measure NAD+ and NADH levels in the blood and myocardium of the participants.

2. Assess mitochondrial morphology and function in cardiac tissue using, respectively, electron microscopy (EM) and isolated mitochondria.

3. Determine protein acetylation in the mitochondrial and non-mitochondrial compartments and changes in nuclear gene regulation.

Aim 3: Test the hypothesis that NR improves mitochondrial function and reduces inflammatory response in heart failure (HF) patients receiving NR (as compared to historical controls).

1. Measure mitochondrial function in peripheral blood mononucleated cells (PBMC).

2. Determine the inflammatory response in PBMC.

3. Compare effects on the circulating inflammasome vs. myocardial inflammation.


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date November 26, 2018
Est. primary completion date November 26, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Diagnosis of advanced heart failure.

- Planned elective LVAD implantation surgery with patient agreements for candidacy in place as required by UWMC.

- Hospital inpatient at time of enrollment.

- Ability to undergo Study procedures.

- Willingness/ability to provide informed consent.

Exclusion Criteria:

- Current smoking

- Receiving certain concurrent supplements (to be determined at discretion of the PI). Note that UWMC Nutrition Care standards call for a general multivitamin (1 tab PO daily) as part of the advanced heart failure therapy (AHFT) work-up.

- Known allergies to niacin or nicotinamide.

- Hepatic, renal, endocrine, or neurological disease that disqualify them from consideration for LVAD implantation.

- Inability to perform Study visits or procedures.

- Unwillingness/inability to provide informed consent.

- Women who are currently pregnant or who wish to become pregnant over the course of the study follow-up are not allowed to join this study. This exclusion is built into the LVAD candidate selection process.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Nicotinamide riboside
nicotinamide riboside supplied as 250mg capsules

Locations

Country Name City State
United States University of Washington Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
University of Washington American Heart Association

Country where clinical trial is conducted

United States, 

References & Publications (1)

Zhou B, Wang DD, Qiu Y, Airhart S, Liu Y, Stempien-Otero A, O'Brien KD, Tian R. Boosting NAD Level Suppresses Inflammatory Activation of PBMC in Heart Failure. J Clin Invest. 2020 Aug 13. pii: 138538. doi: 10.1172/JCI138538. [Epub ahead of print] — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) Adverse Events Up to 14 days
Secondary Effect of NR on whole blood NAD+ levels Change in whole blood NAD+ levels from Baseline to Day of Surgery in NR-treated participants Duration of NR treatment
Secondary Effect of NR on mitochondrial respiration (Seahorse assay) in isolated peripheral blood mononuclear cells (PBMCs) Change in mitochondrial respiration from Baseline to Day of Surgery in NR-treated participants Up to 14 days
Secondary Between-group comparison of whole blood NAD+ levels Comparison of whole blood NAD+ levels on the Day of LVAD Surgery in NR-treated vs. historical control patients Up to 14 days
Secondary Between-group comparison of mitochondrial respiration in PBMCs Comparison of mitochondrial respiration in PBMCs on the Day of LVAD Surgery in NR-treated vs. historical control patients Up to 14 days
See also
  Status Clinical Trial Phase
Withdrawn NCT03519477 - Comprehensive Medication Monitoring on Heart Failure Patient Outcomes N/A
Recruiting NCT05596760 - Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers N/A
Recruiting NCT05227872 - PVF in Decongestion of Heart Failure
Recruiting NCT05543720 - Evaluation of Nurse-led Integrated Care of Complex Patients Facilitated By Telemonitoring: The SMaRT Study N/A
Completed NCT04572425 - Virtual Reality for Pain Management in Advanced Heart Failure N/A
Recruiting NCT03202329 - Evaluation of Post-operative, Nurse-based Heart Failure Care in Non-cardiac Surgery N/A
Recruiting NCT03830957 - Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker N/A
Recruiting NCT02672618 - Clinical Research to Explore Manifestations of Heart Failure Using Infrared Thermal Imaging Technology N/A
Recruiting NCT04179643 - NAN-101 in Patients With Class III Heart Failure Phase 1
Completed NCT04129658 - Heart Failure in Southern Sweden
Not yet recruiting NCT05591443 - Artificial Intelligence and Smart Wearable Technologies for Early Detection of Acute Heart Failure
Completed NCT03387813 - Hemodynamic-GUIDEd Management of Heart Failure N/A
Completed NCT03187470 - Left Ventricular Dyssynchrony in Multipole Pacing N/A
Completed NCT04628325 - Effects of Furosemide Plus Small HSS in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) Phase 3
Completed NCT03385837 - Activity Level and Barriers to Participate of Cardiac Rehabilitation in Advanced Heart Failure Patients
Completed NCT04281849 - Balance, Aerobic Capacity, Mobility and Strength in Patients Hospitalized for Heart Failure (BAMS-HF) Program N/A
Not yet recruiting NCT04403659 - Telemonitoring of Patients Admitted in Hospital at Home With Acute Decompensated Heart Failure - Pilot Study N/A
Terminated NCT04142788 - RELieving Increasing oEdema Due to Heart Failure Phase 4
Active, not recruiting NCT04283994 - Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2) N/A
Completed NCT03722069 - Dietary Sodium Intake in Acute Heart Failure N/A